Vera Therapeutics, Inc. $VERA Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 49.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 165,245 shares of the company’s stock after purchasing an additional 54,942 shares during the quarter. Fifth Third Bancorp owned 0.23% of Vera Therapeutics worth $5,336,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sterling Capital Management LLC boosted its holdings in Vera Therapeutics by 841.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $68,000 after purchasing an additional 1,885 shares during the period. Nykredit A S acquired a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $97,000. Fulcrum Asset Management LLP acquired a new position in shares of Vera Therapeutics during the 3rd quarter worth approximately $74,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Vera Therapeutics during the third quarter worth approximately $119,000. Finally, NINE MASTS CAPITAL Ltd bought a new position in shares of Vera Therapeutics during the second quarter worth approximately $405,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Trading Down 2.9%

VERA opened at $26.20 on Wednesday. Vera Therapeutics, Inc. has a twelve month low of $25.82 and a twelve month high of $56.05. The company has a 50-day simple moving average of $30.75 and a 200 day simple moving average of $36.06. The company has a quick ratio of 7.78, a current ratio of 7.91 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -4.44 and a beta of 1.07.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.30) EPS for the quarter, beating the consensus estimate of ($1.62) by $0.32. The firm had revenue of $10.28 million during the quarter, compared to the consensus estimate of $3.42 million. Analysts predict that Vera Therapeutics, Inc. will post -6.00 EPS for the current fiscal year.

Insider Activity

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of a number of analyst reports. HC Wainwright dropped their price target on shares of Vera Therapeutics from $90.00 to $75.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. Raymond James Financial set a $87.00 price target on Vera Therapeutics in a research report on Friday, November 6th. Wedbush lowered their price objective on Vera Therapeutics from $34.00 to $29.00 and set a “neutral” rating on the stock in a research note on Friday, November 6th. Finally, JPMorgan Chase & Co. lifted their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $74.93.

View Our Latest Report on Vera Therapeutics

Vera Therapeutics Profile

(Free Report)

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.

Featured Stories

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report).

Institutional Ownership by Quarter for Vera Therapeutics (NASDAQ:VERA)

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.